



Efficacy and Safety of Teneiglipitin as Add on Therapy in Indian Type 2 Diabetes Mellitus Patients having Dyslipidemia

Parmar Vinendra M¹, Goswami Sunita S Ph. D scholar

Department of pharmacology, L. M. College of pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India

Abstract:

Objectives: The purpose of this study was to investigate the efficacy and safety of teneiglipitin, a completely unique and highly selective DPP-4 inhibitor in type 2 diabetes mellitus (T2DM) patients having dyslipidemia who are inadequately controlled by relevant conventional therapy in India.

Methods: Study protocol was approved by Institutional Ethics Committee. Diabetic patients having dyslipidemia (male/female) were randomized to receive treatments in two groups, namely conventional therapy [treatment (A)] and add on teneiglipitin 20 mg with conventional therapy [treatment (B)] for 24 weeks. Predesigned case report form (CRF) was used to collect information from the prescribing physicians regarding the efficacy and safety of teneiglipitin. Efficacy variables included change in serum glycaemic, lipid, and cytokines (IL-6, TNF- α and adiponectin) levels from baseline to week 24. Treatment-emergent adverse events (TEAEs) were also assessed.

Results: A complete of 120 T2DM patient having dyslipidemia were analysed using graph pad prism. Teneiglipitin, as add on therapy to conventional therapy significantly reduced serum lipid profile (TC, TG, and LDL) as well as glycaemic parameters (HbA1c, FBG, and PPBG) along with significant rise in serum adiponectin levels as compared to conventional therapy.

Conclusion: Add-on therapy with teneiglipitin was found better option over conventional therapy in term of significantly reduced glycemic as well as lipid profile. Further, it was found safe and well tolerated in T2DM patients having dyslipidemia

Biography: Vinendra Parmar (Ph.D Scholar) is presently working as clinical research scientist at Chemo India formulation, Hyderabad a part of INSUD PHARMA, Spain



Biography:

Shaikha Hassan completing her higher studies in Business Administration at the University of Sharjah and accomplished her BAsC in IT Security and Forensics from the Higher Colleges of Technology in UAE. Before joining Gargash Group, Shaikha worked in the field of digital forensics in Dubai Police Forensic Lab, the largest Forensic Lab in the Middle East and worked in Ministry of the interior for the United Arab Emirates, as well in the fields of IT Infrastructure, IT Project Management, and IT Security. First IEEE academic article had been published for her while she's 21 years old.

Recent Publications:

- Vinendra MP, Sunita SG (2020) Efficacy and Safety of Teneiglipitin as Add on Therapy in Indian Type 2 Diabetes Mellitus Patients having Dyslipidemia
- .Efficacy and Safety of Teneiglipitin as Add on
- Therapy in Indian Type 2 Diabetes Mellitus
- T2DM Patients Having Dyslipidemia
- Efficacy and safety of Teneiglipitin in as add on therapy in Indian Type 2 diabetes mellitus patients having dyslipidemia

Webinar on Forensic Research & Technology : July 27,2020

Citation: Parmar Vinendra M1; Efficacy and Safety of Teneiglipitin; Webinar on Forensic Dactyloscopy 2020; September 29, 2020; Singapore, Singapore